Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the HER2-Positive Breast Cancer Market Size From 2025 to 2034?
The market size of HER2-positive breast cancer has seen significant growth in recent years and it is projected to increase from $10.21 billion in 2024 to $10.93 billion in 2025, with a compound annual growth rate (CAGR) of 7.0%. Contributing factors to this growth during the historic period include enhanced early detection and diagnosis, increased understanding of HER2-positive subtypes, expanded investment in research and development, the rising utilization of precision medicine, and an intensified emphasis on enhancing patient outcomes.
Expectations for the HER2-positive breast cancer market anticipate robust growth over the following few years, with projections indicating a rise to $14.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the prediction period is primarily due to factors such as the escalating demand for non-invasive monitoring through liquid biopsy, the increasing tendency towards the use of combination treatments, heightened concentration on novel drug formulations and immunotherapies, the growing application of liquid biopsy approaches for non-invasive tracking, and the rise in specialty cancer treatment hubs. During the forecast period, major trends encompass advancements in targeted treatment approaches, novel drug formulations, innovative immunotherapy methods, the progression of novel HER2-centric therapies, and developments in biomarkers for improved patient classification.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp
What are the Fundamental Drivers and Innovations Shaping the HER2-Positive Breast Cancer Market?
The expansion of the HER2-positive breast cancer market is projected to be fueled by the robust uptake of immunotherapy. Immunotherapy is a medical practice that augments or alters the natural disease-fighting ability of the immune system, applicable in conditions like infections, cancer, and autoimmune diseases. Its appeal comes from its potential to amplify the immune system’s capacity to detect and eliminate cancer cells, thereby offering greater efficiency and lesser side effects compared to traditional therapies. Immunotherapy helps HER2-positive breast cancer by boosting the body’s immune system to identify and combat HER2-overexpressing cancer cells, thus improving therapeutic results and diminishing the chance of relapse. For example, in July 2023, the American Association for Cancer Research, a United States-based body, reported that the FDA had given its approval for 11 immune checkpoint inhibitors (ICIs), with at least one ICI sanctioned for use in 20 distinct types of cancer and for any solid tumor showing particular molecular features. Consequently, the vigorous uptake of immunotherapy is the driving force behind the development of the HER2-positive breast cancer market.
How Is the HER2-Positive Breast Cancer Market Segmented?
The her2-positive breast cancermarket covered in this report is segmented –
1) By Treatment Type: Targeted Therapy; Chemotherapy; Endocrine Therapy; Immunotherapy; Other Treatment Types
2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End User
Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab); Tyrosine Kinase Inhibitors (TKIs); Antibody-Drug Conjugates (ADC); Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy; Taxane-based Chemotherapy; Platinum-based Chemotherapy; Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Antagonists; Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors); Monoclonal Antibodies for Immune Modulation; Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy; Stem Cell Therapy; Hyperthermia Treatment; Gene Therapy; Surgical Interventions (Mastectomy, Breast Conserving Surgery)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20832&type=smp
Which Regions Are Driving the Next Phase of the HER2-Positive Breast Cancer Market Growth?
North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the HER2-Positive Breast Cancer Market?
Leading entities within the HER2-positive breast cancer market are enhancing patient treatment by establishing inventive therapies, such as HER2-focused antibody-drug conjugates (ADCs). These are specialized cancer treatments that couple a HER2-specific antibody with a cytotoxic drug, channeling the drug directly towards HER2-positive cancer cells for maximum efficiency. For example, in January 2024, AstraZeneca India Pharma Ltd., an India-headquartered biopharmaceutical enterprise, introduced Trastuzumab deruxtecan. This trailblazing therapy was born out of a collaboration between AstraZeneca and Daiichi Sankyo. As a HER2-oriented antibody-drug conjugate (ADC), Trastuzumab deruxtecan delivers a cytotoxic drug directly towards HER2-positive cancer cells, promising a more focused and robust treatment for patients.
View the full report here:
https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report
How Is the HER2-Positive Breast Cancer Market Defined and What Are Its Core Parameters?
HER2-positive breast cancer refers to a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth of cancer cells and is found in approximately 15-20% of breast cancers. HER2-positive breast cancer is generally more aggressive than HER2-negative forms but is treatable with targeted therapies that inhibit HER2 activity.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20832
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model